Leap Therapeutics Inc. (LPTX)
Leap Therapeutics Statistics
Share Statistics
Leap Therapeutics has 41.44M shares outstanding. The number of shares has increased by 7.82% in one year.
| Shares Outstanding | 41.44M |
| Shares Change (YoY) | 7.82% |
| Shares Change (QoQ) | 7.67% |
| Owned by Institutions (%) | 51.49% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 299 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.46M, so 8.39% of the outstanding shares have been sold short.
| Short Interest | 3.46M |
| Short % of Shares Out | 8.39% |
| Short % of Float | 9.84% |
| Short Ratio (days to cover) | 5.03 |
Valuation Ratios
The PE ratio is -1.6 and the forward PE ratio is -0.61. Leap Therapeutics's PEG ratio is 0.03.
| PE Ratio | -1.6 |
| Forward PE | -0.61 |
| PS Ratio | 0 |
| Forward PS | 0.5 |
| PB Ratio | 3.09 |
| P/FCF Ratio | -1.79 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Leap Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.41, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.41 |
| Quick Ratio | 3.41 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,303,634.62 |
| Employee Count | 52 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -585K |
| Effective Tax Rate | 0.87% |
Stock Price Statistics
The stock price has increased by -87.07% in the last 52 weeks. The beta is 0.21, so Leap Therapeutics's price volatility has been higher than the market average.
| Beta | 0.21 |
| 52-Week Price Change | -87.07% |
| 50-Day Moving Average | 0.39 |
| 200-Day Moving Average | 2 |
| Relative Strength Index (RSI) | 54.26 |
| Average Volume (20 Days) | 2,303,073 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -70.06M |
| Net Income | -67.79M |
| EBITDA | -70.06M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.81 |
Balance Sheet
The company has 47.25M in cash and 266K in debt, giving a net cash position of 46.98M.
| Cash & Cash Equivalents | 47.25M |
| Total Debt | 266K |
| Net Cash | 46.98M |
| Retained Earnings | -467.37M |
| Total Assets | 49.12M |
| Working Capital | 33.96M |
Cash Flow
In the last 12 months, operating cash flow was -60.3M and capital expenditures 0, giving a free cash flow of -60.3M.
| Operating Cash Flow | -60.3M |
| Capital Expenditures | n/a |
| Free Cash Flow | -60.3M |
| FCF Per Share | -1.61 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LPTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for LPTX is $8, which is 1851.2% higher than the current price. The consensus rating is "Hold".
| Price Target | $8 |
| Price Target Difference | 1851.2% |
| Analyst Consensus | Hold |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Jun 21, 2023. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 21, 2023 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | -16.51 |
| Piotroski F-Score | 1 |